학술논문

Diagnosis and treatment of viral liver fibrosis
Document Type
article
Source
The Saudi Journal of Gastroenterology, Vol 11, Iss 1, Pp 1-19 (2005)
Subject
Fibrotest
Actitest
FibroSURE
fibrosis biomarker
activity biomarker
liver biopsy limits
HCV
HBV
Alcoholic liver disease
fatty liver.
Diseases of the digestive system. Gastroenterology
RC799-869
Language
English
ISSN
1319-3767
Abstract
This review summarized the diagnostic value of fibrosis biomarkers and the efficacy of anti-viral treatments on fibrosis progression. Non-invasive biomarkers can facilitate the screening and management of chronic hepatitis C and B. Screening for significant fibrosis is-mandatory as very effective anti-viral treatments are available, permitting to stop or to reduce the fibrosis progression. The reduction of fibrosis progression will decrease the mortality due to complications of cirrhosis. In patients with chronic hepatitis C, pegylated interferons combined with ribavirin are effective in reducing fibrosis progression. In patients with chronic hepatitis B, lamivudine, adefovir and pegylated interferon are also effective in reducing fibrosis progression. In patients with chronic hepatitis Delta, pegylated interferon is also effective in reducing fibrosis progression